2023年8月18日,

披露:豪泽报告支付从Amneal制药南佛罗里达大学期间进行现场试验研究的行为;接受咨询和/或从AbbVie演讲费,Acorda, AgeX疗法,Amneal制药、蓝色石头疗法,全球动力学,Cerevel, Inhibikase,爵士乐制药、Kyowa麒麟,地中海节奏,梅尔兹,神经内分泌的生物科学,NeuroDerm,奥维德疗法,PD脑科学,医药两个B, Regenxbio,圣人疗法,接穗Neurostim, Supernus制药、Tolmar, TrisPharma,联合银行,和Vivifi生物技术在提交工作;持有股票期权在Inhibikase Enterin;南佛罗里达大学拥有版权的帕金森日记豪泽博士收到费用。主题添加到邮件提醒收到一封电子邮件在发布新文章时请提供您的电子邮件地址来接收电子邮件当张贴新文章。请稍后再试。如果你继续这个问题请联系customerservice@slackinc.com。回到Healio IPX203导致1.55小时以上的‘好’每剂准时而CD / LD。口服,延长释放治疗提供了更多的‘好’准时在更少的日常剂量与速释左旋多巴/卡比多巴在帕金森病运动波动,根据在JAMA神经学的研究表明。“IPX203,一个新的口服,延长释放carbidopa-levodopa胶囊能解决的血浆半衰期短,有限的吸收窗口(左旋多巴),”罗伯特·豪泽,医学博士、MBA,南佛罗里达大学的帕金森病和运动障碍中心,和他的同事写道。 According to new research, an investigational oral, extended-release therapeutic provided more relief in fewer daily doses compared with immediate-release standard treatment in those with PD-related motor fluctuations. Image: Adobe Stock Researchers aimed to assess safety and efficacy of novel therapeutic IPX203 compared with immediate-release carbidopa-levodopa in those with Parkinson’s disease and motor fluctuations. They conducted the RISE-PD study, a 20-week, randomized, double-blind active-controlled, phase 3 clinical trial at 105 academic and clinical centers throughout the United States and Europe. A total of 630 patients (mean age 66.5 years; 62.9% men) were enrolled with 506 participants who were randomly assigned 1:1 to receive either IPX203 (n=256) or immediate-release carbidopa-levodopa (n=250) following a 3-week open-label, immediate-release carbidopa-levodopa dose adjustment. The study’s primary endpoint was mean change in daily good on-time (without troublesome dyskinesia) from baseline to the end of the 13-week double-blind treatment period. According to results, treatment with IPX203 demonstrated statistically significant improvement in daily “good” on-time for fewer doses of IPX203 compared with immediate-release carbidopa-levodopa (least squares mean, 0.53 hours; 95% CI, 0.09-0.97), with IPX203 dosed a mean three times per day compared with immediate-release carbidopa-levodopa dosed five times per day. Data additionally showed that “good” on-time per dose increased by nearly 2 hours with IPX203 compared with immediate-release carbidopa-levodopa (95% CI, 1.37-1.73). IPX203 was also well tolerated, with the most common adverse events in the double-blind phase (IPX203 vs. immediate-release carbidopa-levodopa) being nausea (4.3% vs. 0.8%) and anxiety (2.7% vs 0%). “These results suggest that IPX203 may be useful in patients with motor fluctuations to provide more sustained benefit throughout the day,” Hauser and colleagues wrote.